Breaking News

AbbVie to Acquire ImmunoGen in $10.1B Deal

Will gain flagship cancer therapy ELAHERE, expanding its solid tumor portfolio.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie Inc. entered a definitive agreement to acquire ImmunoGen for approximately $10.1 billion, gaining its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition expands AbbVie’s commercial and clinical presence in the solid tumor space. ImmunoGen’s follow-on pipeline of  next-gen ADCs complements AbbVie’s ADC platform and existing programs.   ELA...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters